Laboratory assistant

Virus & Vaccines

Virus & Vaccines

We pride ourselves in being a global leader in the development of vaccine & viral vector formulations —whether liquid, lyophilized or spray-dried—for a large variety of ATMP and vaccine types. Our database and algorithms, together with our expertise, help to make the impossible possible and provide tailored and best-in-class formulations for your specific vaccine / virus. Some of our examples in the field of ATMPs and vaccines are shown below.

Case Study

Liquid

Liquid

Best-in-class formulations for Ad5 viruses and viral vectors

Best-in-class formulations for Ad5 viruses and viral vectors

Uploaded

Internal R&D project implementing an excipient preselection approach, enabling rational formulation development and the generation of best-in-class formulations for Ad5 viruses and viral vectors in liquid.

Case Study

Lyophilized

Lyophilized

Customer project (oncology) to stabilize human adenovirus in lyophilized form: Leukocare successfully stabilized an adenovirus with undisclosed insert during lyophilization and storage for at least 24 months. After lyophilization titer drop was < 0.3 log; total titer drop during lyophilization and storage was < 0.4 log.

Stabilization of human adenovirus (ATMP)

Stabilization of human adenovirus (ATMP)

Uploaded
Case Study

Influenza vaccine

Development of an influenza vaccine as dry powder

Development of an influenza vaccine as dry powder

Uploaded

R&D collaboration with Christian-Albrechts-University (Kiel, Germany): Development of an influenza vaccine as dry powder to increase stability, enable terminal sterilization, and to utilize alternative routes of administration.
Immune response in non-human primates was fully retained after spray-drying and irradiation with Leukocare formulation compared to non-irradiated original influenza vaccine.
Storage at ambient conditions (25°C and 60% relative humidity) did not show an influence on the antigen integrity and activity.


Immune response in macaques to influenza vaccine (HAI titer), PBS=negative control. *significantly different (p < 0.01) from group 2, 4 and 5 mean titers of groups 2, 4 and 5 were not significantly different from one another (bars represent the geometric mean titer for each group)

Enveloped Viruses and Non-Enveloped Viruses

DNA, enveloped
  • Poxviridae (e.g. modified vaccinia virus Ankara (MVA))

  • Herpesviridae

DNA, non-enveloped
  • Adeno-associated virus (AAV)

  • Adenovirus (Ad)

  • Parvovirus

RNA, enveloped
  • Rhabdoviridae

  • Coronaviridae

  • Arteriviridae

  • Togaviridae

  • Paramyxovirus strains

  • Influenza strains

  • Lentivirus

RNA, non-enveloped
  • Picornavirus

Interested in Molecular Modeling to understand the cQAs of your product?

Laboratory assistant

Interested in Molecular Modeling to understand the cQAs of your product?

Laboratory assistant

Interested in fill and finish services for non-clinical tox studies?

Laboratory assistant

FAQ

Which molecule classes do you work with most often?
What is SMART Formulation® and how does it differ from classic screening?
How long does a typical formulation project take?
Can you supply non-GMP material for pre-clinical studies?

FAQ

Which molecule classes do you work with most often?
What is SMART Formulation® and how does it differ from classic screening?
How long does a typical formulation project take?
Can you supply non-GMP material for pre-clinical studies?

FAQ

Which molecule classes do you work with most often?
What is SMART Formulation® and how does it differ from classic screening?
How long does a typical formulation project take?
Can you supply non-GMP material for pre-clinical studies?